On September 24, Natera rose 3.22% in regular trading, trading at $403.35 per share, with turnover of $66.27 million.
On the news front, Japan's Pharmaceuticals and Medical Devices Agency approved Natera's Signatera test as a companion diagnostic for muscle-invasive bladder cancer, supporting adjuvant atezolizumab treatment decisions. The approval was based on data from the Phase III IMvigor011 clinical trial, and the company expects to commercially launch the test in Japan in H1 of next year. This marks the second indication for Signatera in Japan following the colorectal cancer MRD testing approval in June, further broadening its international commercialization footprint.
Additionally, multiple investment banks recently raised their price targets on Natera. UBS lifted its target from $290 to $435 while maintaining a Buy rating, and Rothschild initiated coverage with a Buy rating and a $385 price target. The FDA had previously approved Signatera CDx as a companion diagnostic in muscle-invasive bladder cancer in May, and the test also received EU IVDR Class C certification in July, reinforcing its global regulatory momentum.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments